Looking for molecules similar to the one you already know? Our Molport Similarity Search tool makes it simple to explore related compounds and expand your options. Begin by identifying your molecule using SMILES, CAS Number, Molport ID, or other unique identifiers. From the molecule’s page, just one click launches a search for similar structures—ready for you to filter, review, and refine. Prefer a hands-on approach? You can also draw your own structure, convert identifiers, set…
From Apothecary to Alkaloid Pioneer: The Origins of Merck and Modern Drug Discovery Did you know that Merck, one of the oldest pharmaceutical companies in the world, played a foundational role in the development of alkaloid chemistry, laying the groundwork for modern medicinal chemistry and compound screening? The story begins in 1668, when Friedrich Jacob Merck purchased the Engel-Apotheke (Angel Pharmacy) in Darmstadt, Germany. However, the real transformation occurred in 1827, when Heinrich Emanuel Merck…
Need to source multiple compounds quickly and efficiently? The Molport List Search tool allows you to search for up to 10,000 compounds simultaneously, providing instant access to availability, pricing, lead times, and supplier details. With just a free registration, you can upload your list in SD or SMILES format, or paste SMILES/MolPort IDs directly from Excel. In just a few steps, you’ll receive the best offer calculation, download quotes in multiple formats, and even place your order online. Whether…
August 25th The Logic of Chemical Optimization https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5c00445 Abstract During multiparameter chemical optimization, molecular capabilities increase as hits evolve into leads and development candidates. Like retrosynthetic analysis, where target molecules are transformed into structurally simplified starting materials, we introduce retro-optimization analysis, transforming sophisticated development candidates into less capable leads and hits. To retrospectively understand the logic of optimization in discovery campaigns, we enumerated a matched molecular pair network and compared the actual route of optimization…
Looking to explore Molport’s rich compound data for your research? In this quick tutorial, we walk you through three simple ways to access the Molport Database—whether you prefer a direct download, advanced FTP access, or seamless API integration. Learn which option best fits your needs, how to get started, and where to request access. Watch now to make the most of Molport’s powerful resources. 🎥 Watch the full tutorial here: Molport Database Access Options
July 28th Discovery of a New Class of Orexin 2 Receptor Agonists as a Potential Treatment for Narcolepsy https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5c00362 Abstract The orexinergic system, projecting from the lateral hypothalamus, operates through two receptors, orexin receptor type-1 (OX1) and orexin receptor type-2 (OX2), stabilizing wakefulness, mainly via OX2. Narcolepsy Type 1 (NT1) is characterized by excessive sleepiness and cataplexy, and is linked to a loss of orexin-producing neurons. Current therapies manage the symptoms but do not address…
Toxicology and Preclinical Testing (Animal Models) Today, I would like to share with you the story of another individual who made a remarkable contribution to the history of drug development. The person who laid the basis for modern preclinical animal model tox evaluations was Johann Wepfer (1620–1695). A Swiss Pioneer of Toxicology and Preclinical Testing (Animal Models). Long before modern drug development, Wepfer made groundbreaking strides in toxicological analysis. He is best known for his…
June 23rd Characterizing and understanding the formation of cysteine conjugates and other by-products in a random, lysine-linked antibody drug conjugate https://www.tandfonline.com/doi/full/10.1080/19420862.2021.1974150#abstract Abstract This study describes the characterization of conjugation sites for a random, lysine conjugated 2-iminothiolane (2-IT) based antibody-drug-conjugate synthesized from an IgG1 antibody and a duocarmycin analog-based payload-linker. Of the 80 putative lysine sites, 78 were found to be conjugated via tryptic peptide mapping and LC-HRMS. Surprisingly, seven cysteine-linked conjugated peptides were also detected…
May 12th Real Way to Target Gram-Negative Pathogens: Discovery of a Novel Helicobacter pylori Antibiotic Class https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5c00112 Abstract In an era of escalating antibiotic resistance, there is a pressing need for innovative strategies to develop novel antibiotics. Gram-negative bacteria, characterized by their robust dual-membrane, are intrinsically resistant to a wide range of antibiotics and can readily develop new resistances. Members of this bacterial class comprise numerous pathogenic organisms, including the primary cause of gastric cancer, Helicobacter pylori. In…
Dose Makes The Poison Today I’d like to tell you about a Swiss gentleman named Paracelsus. Often called the “father” of modern toxicology and pharmacology, Paracelsus was the first to articulate a principle that still underpins toxicology today: “The dose makes the poison.” He argued that no substance is inherently toxic; it all depends on how much of it you take. Even substances we consider harmful can be beneficial in tiny amounts. Paracelsus famously used…
